Oct 16, · Recurrent respiratory papillomatosis is a noninvasive benign epithelial tumor caused by human papillomavirus. Clinically, it featured rapid growth, multifocus, and frequent recurrence. Though a number of therapies have been investigated, the recurrence after treatment is always a challenge. In this report, we describe a year-old male patient with recurrent respiratory papillomatosis who was Author: Sheng Lu, Yang Liu, Runjie Shi, Pingyu Zhou. Objectives/hypothesis: To evaluate risk factors strongly associated with adult-onset recurrent respiratory papillomatosis (AO-RRP). Study design: Prospective, age- and sex-matched, case control. Methods: Patients with AO-RRP and controls completed a computer-based, item questionnaire across three academic institutions. Results: Forty-eight AO-RRP patients were compared to 73 controls; 43 of Cited by:
Apr 28, · Recurrent respiratory papillomatosis (RRP) is a rare viral disease where tumors (papillomas) grow in the air passages leading from the nose and mouth into the lungs (respiratory tract). There are two types, a juvenile-onset form and an adult-onset form. The tumors can cause a hoarse voice, chronic cough, and difficulty breathing. Recurrent respiratory papillomatosis (RRP) is a rare disease (there are perhaps active cases in the U.S.) that is characterized by the growth of tumors in the respiratory tract caused by the human papilloma virus (HPV). The distribution of diagnosis ages is much broader for adult onset RRP (AORRP) than for children, as RRP may present.
Risk factors for adult-onset recurrent respiratory papillomatosis. Ruiz R(1), Achlatis S, Verma A, Born H, Kapadia F, Fang Y, Pitman M, Sulica L, Branski RC, Amin MR. Author information: (1)NYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York, New York, cunty.xyz by: Jul 24, · Recurrent respiratory papillomatosis manifests clinically as exophytic, bulky lesions, with a predilection for the junction between stratified squamous and respiratory columnar epithelium. 25 Fewer than 1 in 5 adult patients will develop spread of disease to the lungs, although this figure is higher in the juvenile variant. 26 Death secondary Cited by: